Microbiota Community of Irritable Bowel Syndrome in Episodes and Remission Phase
NCT02566629 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2015-10-02
Summary
Analyze microbiota community of irritable bowel syndrome in episodes phase and remission phase.
Conditions
- Irritable Bowel Syndrome
Interventions
- OTHER
-
collect faeces from participants
analyze the fecal microbiota community using 16S rDNA detection technique
Sponsors & Collaborators
-
Shandong University
lead OTHER
Principal Investigators
-
Yanqing Li, MD.PhD · Qilu Hospital of Shandong University
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2015-07-31
- Primary Completion
- 2015-11-30
- Completion
- 2015-11-30
Countries
- China
Study Locations
More Related Trials
-
Pathophysiological Effects of Persistently Colonized Microbiome on Irritable Bowel Syndrome
NCT06013410 ·Status: RECRUITING ·Phase: NA
-
Efficacy of Probiotics in Patients With IBD
NCT05652621 ·Status: RECRUITING ·Phase: NA
-
FMT for Patients With IBS With Fecal and Mucosal Microbiota Assessment
NCT03125564 ·Status: COMPLETED ·Phase: NA
-
Changes of Microbiota in Irritable Bowel Syndrome Patients
NCT01679730 ·Status: UNKNOWN
-
Efficacy and Safety Evaluation of Fecal Microbiota Transplantation in Irritable Bowel Syndrome
NCT05740319 ·Status: RECRUITING ·Phase: NA
-
Comparison of Microbiota and Quality of Life for a Low FODMAPs and Standard Dietary in Irritable Bowel Syndrome Patients
NCT02902926 ·Status: UNKNOWN ·Phase: NA
-
Study on the Molecular Mechanism of Diarrhea-predominant Irritable Bowel Syndrome With Anxiety and Depression Based on Multi-omics Correlation Analysis
NCT05311293 ·Status: UNKNOWN
-
Efficacy and Safety of Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome
NCT06697119 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Efficacy of Rifaximin to Treat Diarrhea-predominant Irritable Bowel Syndrome
NCT02565654 ·Status: UNKNOWN
-
Efficacy of Repeated Transcranial Magnetic Stimulation Combined With a Live Probiotic Tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live) in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
NCT06960369 ·Status: RECRUITING ·Phase: PHASE1
-
Efficacy and Safety of FMT for the Treatment of IBS-D and Mental Health Comorbidity in Young Adults
NCT06297421 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Gut Microbiota in Chronic GI Diseases
NCT06532110 ·Status: RECRUITING
-
Efficacy of a Probiotic Blend to Reduce Gastrointestinal Symptoms in Patients With Irritable Bowel Syndrome
NCT05819281 ·Status: UNKNOWN ·Phase: PHASE2
-
Fecal Microbiota Transplantation to Relieve Symptoms of Irritable Bowel Syndrome Without Constipation
NCT05803980 ·Status: RECRUITING ·Phase: NA
-
The Effect of Prebiotics on the Microbiome in Irritable Bowel Syndrome Patients: The Diet and Microbiome Study
NCT01829932 ·Status: COMPLETED ·Phase: NA
-
The Role of Intestinal Inflammation in Irritable Bowel Syndrome (IBS)
NCT01072903 ·Status: COMPLETED
-
Fecal Microbiota Transplantation in Irritable Bowel Syndrome With Bloating
NCT02299973 ·Status: COMPLETED ·Phase: NA
-
Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome
NCT02092402 ·Status: COMPLETED ·Phase: NA
-
Microbe-Gut Interaction in Microscopic Colitis and Post-Infectious Irritable Bowel Syndrome (IBS)
NCT01787253 ·Status: COMPLETED
-
Effect of Fecal Microbiota Transplantation in Irritable Bowel Syndrome
NCT02788071 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Fecal Microbiota Transplantation to Relieve Symptoms of Irritable Bowel Syndrome With Constipation
NCT05803993 ·Status: RECRUITING ·Phase: NA
-
Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D
NCT04074421 ·Status: UNKNOWN ·Phase: PHASE4
-
Diagnostic Strategies in Patients Suspected of Irritable Bowel Syndrome
NCT00659763 ·Status: COMPLETED
-
Developing Novel Microbiota-Targeted Therapies for Irritable Bowel Syndrome
NCT02249169 ·Status: COMPLETED
-
Effect of Clostridium Butyricum in Treating Irritable Bowel Syndrome
NCT02614963 ·Status: UNKNOWN ·Phase: PHASE4